Medivir (LSE:0GP7) - Cours de l'action, nouvelles et analyse

0GP7 Aperçu des actions

A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. Plus de détails

0GP7 analyse fondamentale
Score flocon de neige
Évaluation	0/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 58.84% par an

Analyse des risques

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Réalise moins d'un million de dollars de revenus ( SEK8M )

Les actions sont très illiquides

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

+ 1 plus de risques

Medivir AB (publ) Concurrents

Oncimmune Holdings

AIM:ONC

UK£17.2m

OptiBiotix Health

AIM:OPTI

UK£12.2m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Aptamer Group

AIM:APTA

UK£6.5m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Medivir
Historique des cours de bourse
Prix actuel de l'action	SEK 2.93
Plus haut sur 52 semaines	SEK 7.35
Plus bas sur 52 semaines	SEK 2.93
Bêta	-0.17
1Variation sur 1 mois	0%
Variation sur 3 mois	n/a
Variation sur 1 an	-58.19%
3Variation sur 3 ans	-64.70%
Variation sur 5 ans	-84.69%
Évolution depuis l'introduction en bourse	-95.12%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	0GP7	GB Biotechs	GB Marché
7D	0%	2.0%	1.7%
1Y	-58.2%	-17.5%	8.3%

Rendement vs Industrie: 0GP7 a sous-performé le secteur UK Biotechs qui a rapporté -17.5 % au cours de l'année écoulée.

Rendement vs marché: 0GP7 a sous-performé le marché UK qui a rapporté 8.3 % au cours de l'année écoulée.

Volatilité des prix

Is 0GP7's price volatile compared to industry and market?
0GP7 volatility
0GP7 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Cours de l'action stable: 0GP7 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de 0GP7 au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1987	10	Jens Lindberg	www.medivir.com

Medivir AB (publ) Résumé des fondamentaux

Comment les bénéfices et les revenus de Medivir se comparent-ils à sa capitalisation boursière ?
0GP7 statistiques fondamentales
Capitalisation boursière	SEK 348.84m
Bénéfices(TTM)	-SEK 96.52m
Recettes(TTM)	SEK 7.73m

45.1x

Ratio P/S

-3.6x

Ratio P/E

Le site 0GP7 est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
0GP7 compte de résultat (TTM)
Recettes	SEK 7.73m
Coût des recettes	SEK 76.47m
Marge brute	-SEK 68.73m
Autres dépenses	SEK 27.79m
Les revenus	-SEK 96.52m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

Aug 22, 2024

Résultat par action (EPS)	-0.86
Marge brute	-888.81%
Marge bénéficiaire nette	-1,248.18%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de 0GP7?

Voir les performances historiques et les comparaisons

0GP7 Aperçu des actions

Récompenses

Analyse des risques

Medivir AB (publ) Concurrents

AIM:ONC

UK£17.2m

AIM:OPTI

UK£12.2m

AIM:TRX

UK£40.6m

AIM:APTA

UK£6.5m

Historique des prix et performances

Nouvelles et mises à jour récentes

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Recent updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

High number of new and inexperienced directors

Full year 2023 earnings released: kr1.48 loss per share (vs kr1.59 loss in FY 2022)

High number of new and inexperienced directors

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

High number of new and inexperienced directors

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

High number of new and inexperienced directors

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

New major risk - Revenue size

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Medivir AB (publ) Résumé des fondamentaux

45.1x

-3.6x

Bénéfices et recettes